BioSpace News Archive

Sensei Biotherapeutics, Inc. today announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted nine employees nonqualified stock options to purchase an aggregate of 72,300 shares of its common stock with an exercise price of $3.03, which is equal to the closing price of Gritstone’s common stock on November 11, 2022, the date of the grant.

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies and advanced science to find new solutions for devastating cancers and immune disorders, has been recognized as a Top Workplaces 2022 award winner by the San Diego Union-Tribune.

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company’s CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin in front line therapy in patients with sarcoma (NCT 05448820).

Rhythm Pharmaceuticals, Inc. announced that Great Britain’s Medicines & Healthcare products Regulatory Agency has expanded the marketing authorization for IMCIVREE® to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome in adult and pediatric patients 6 years of age and older.

Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced the signing of an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.

SAB Biotherapeutics today announced SAB-142 is being progressed as a therapeutic agent to prevent and/or delay onset and progression of Type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases.

Genmab A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20).

Femasys Inc. today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace.

Blue Earth Diagnostics today announced presentations on investigational rhPSMA compounds and Axumin® (fluciclovine F 18) at the upcoming 23rd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in San Diego, Calif., from November 30 to December 2, 2022.